Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-29

Clinical Trial Update: A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin [Phase 3]

View source ↗

Summary

Phase 3 trial assessing reversal of Hepatorenal Syndrome Type 1 with terlipressin; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Terlipressin (terlipressin)

Snippet

Sponsor: Mallinckrodt | Conditions: Hepatorenal Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2022-11-29